BACKGROUND: Delay in the diagnosis of breast cancer is associated with worse stage distribution at diagnosis and decreased survival. However, the occurrence of delay in the delivery of adjuvant therapy and its impact on prognosis is not well understood. METHODS: To investigate the timeliness of initiation of adjuvant chemotherapy following surgery for breast cancer, we used data from the Surveillance, Epidemiology, and End-Results (SEER)-Medicare database. Among women > or = 65 years diagnosed between 1992 and 1999 with stages I-II breast cancer, we used linear regression and Cox proportional hazards models to investigate the time intervals between surgery and initiation of adjuvant chemotherapy, factors associated with delay, and the effect of delay on survival. RESULTS: Our sample consisted of 5003 women who received adjuvant chemotherapy. Of these, 47% initiated chemotherapy within 1 month, 37% between 1 and 2 months, 6% between 2 and 3 months and 10% >3 months (delay) following surgery. Delay was associated with increasing age, residing in a rural location, being unmarried, earlier tumor stage, hormone receptor positivity, mastectomy, and non-receipt of radiation therapy. Survival did not differ among patients who initiated chemotherapy within 1, 2, or 3 months after surgery. Delay beyond 3 months was, however, associated with increased disease-specific mortality (HR 1.69; 95% CI 1.31-2.19) and overall mortality (HR 1.46; 95% CI 1.21-1.75). CONCLUSIONS: Among older patients, moderate delays in the receipt of adjuvant chemotherapy occur frequently, but long delays (>3 months) are uncommon. While early initiation of therapy is no benefit, significant delays are associated with increased mortality. Whether this reflects the medical impact of the delay of chemotherapy or factors associated with delay is unclear, but until this is clarified, patients should be encouraged to initiate treatment without significant delay.
BACKGROUND: Delay in the diagnosis of breast cancer is associated with worse stage distribution at diagnosis and decreased survival. However, the occurrence of delay in the delivery of adjuvant therapy and its impact on prognosis is not well understood. METHODS: To investigate the timeliness of initiation of adjuvant chemotherapy following surgery for breast cancer, we used data from the Surveillance, Epidemiology, and End-Results (SEER)-Medicare database. Among women > or = 65 years diagnosed between 1992 and 1999 with stages I-II breast cancer, we used linear regression and Cox proportional hazards models to investigate the time intervals between surgery and initiation of adjuvant chemotherapy, factors associated with delay, and the effect of delay on survival. RESULTS: Our sample consisted of 5003 women who received adjuvant chemotherapy. Of these, 47% initiated chemotherapy within 1 month, 37% between 1 and 2 months, 6% between 2 and 3 months and 10% >3 months (delay) following surgery. Delay was associated with increasing age, residing in a rural location, being unmarried, earlier tumor stage, hormone receptor positivity, mastectomy, and non-receipt of radiation therapy. Survival did not differ among patients who initiated chemotherapy within 1, 2, or 3 months after surgery. Delay beyond 3 months was, however, associated with increased disease-specific mortality (HR 1.69; 95% CI 1.31-2.19) and overall mortality (HR 1.46; 95% CI 1.21-1.75). CONCLUSIONS: Among older patients, moderate delays in the receipt of adjuvant chemotherapy occur frequently, but long delays (>3 months) are uncommon. While early initiation of therapy is no benefit, significant delays are associated with increased mortality. Whether this reflects the medical impact of the delay of chemotherapy or factors associated with delay is unclear, but until this is clarified, patients should be encouraged to initiate treatment without significant delay.
Authors: Jamie L Wagner; Carla L Warneke; Elizabeth A Mittendorf; Isabelle Bedrosian; Gildy V Babiera; Henry M Kuerer; Kelly K Hunt; Wei Yang; Aysegul A Sahin; Funda Meric-Bernstam Journal: Ann Surg Date: 2011-07 Impact factor: 12.969
Authors: Angela K Green; Emeline M Aviki; Konstantina Matsoukas; Sujata Patil; Deborah Korenstein; Victoria Blinder Journal: Breast Cancer Res Treat Date: 2018-08-09 Impact factor: 4.872
Authors: Alok Kapoor; Tracy A Battaglia; Alexis P Isabelle; Amresh D Hanchate; Richard L Kalish; Sharon Bak; Rebecca G Mishuris; Swati M Shroff; Karen M Freund Journal: J Health Care Poor Underserved Date: 2014-02
Authors: Rachel Yung; Roberta M Ray; Joshua Roth; Lisa Johnson; Greg Warnick; Garnet L Anderson; Candyce H Kroenke; Rowan T Chlebowski; Michael S Simon; Chunkit Fung; Kathy Pan; Di Wang; Wendy E Barrington; Kerryn W Reding Journal: Breast Cancer Res Treat Date: 2020-02-15 Impact factor: 4.872
Authors: Ali Johnson; Leanne Shulman; Jennifer Kachajian; Brian L Sprague; Farrah Khan; Ted James; David Cranmer; Peter Young; Ruth Heimann Journal: J Oncol Pract Date: 2016-08-30 Impact factor: 3.840
Authors: Vanessa B Sheppard; Claudine Isaacs; George Luta; Shawna C Willey; Marc Boisvert; Felicity W K Harper; Karen Smith; Sara Horton; Minetta C Liu; Yvonne Jennings; Fikru Hirpa; Felicia Snead; Jeanne S Mandelblatt Journal: Breast Cancer Res Treat Date: 2013-04-16 Impact factor: 4.872
Authors: Tracy A Battaglia; M Christina Santana; Sharon Bak; Manjusha Gokhale; Timothy L Lash; Arlene S Ash; Richard Kalish; Stephen Tringale; James O Taylor; Karen M Freund Journal: Cancer Date: 2010-02-15 Impact factor: 6.860
Authors: Mariana Chavez-MacGregor; Christina A Clarke; Daphne Y Lichtensztajn; Sharon H Giordano Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777